Paula und Bobby
Eltern von Lillie
Mucopolysaccharidosis, Type IIIC
Was ist Mucopolysaccharidosis, Type IIIC?
It is a subtype of Mucopolysaccharidosis, Type III. There are four subtypes of this form of the syndrome. Known as a form of childhood dementia the syndrome causes brain damage that is eventually fatal.
Type C is the mildest subtype of the syndrome. It’s symptoms are less severe than the other three types, and affected individuals generally have a higher life expectancy, usually into early adulthood.
This syndrome is also known as:
Acetyl-coa:alpha-glucosaminide N-acetyltransferase Deficiency MPS IIIA-D Mps Iiic MPSIII Mucopolysaccharidosis III Mucopolysaccharidosis type III Sanfilippo Syndrome C
Was Genveränderungen verursachen Mucopolysaccharidosis, Type IIIC?
Veränderungen im HGSNAT-Gen sind für die Auslösung des Syndroms verantwortlich.
Es wird autosomal-rezessiv vererbt.
Was sind die wichtigsten symptome von Mucopolysaccharidosis, Type IIIC?
Symptoms of the syndrome do not usually present at birth. One of the first symptoms recognised is developmental delay which is usually identified in early childhood and before the age of 6. From this age the symptoms become more severe, and intellectual ability starts to decline. Behavioral issues, including hyperactivity, are also a major symptom and often one of the first identified. Sleeping issues are also common. Affected individuals will also experience speech delay which gets progressively worse with age.
Physical features of the syndrome include coarse hair, excessive hair growth, coarse facial features, and hearing and vision loss. Enlarged organs such as the liver and/or spleen and hernias are also features of the syndrome.
Possible clinical traits/features:
Dysphagia, Dysostosis multiplex, Everted lower lip vermilion, Coarse hair, Coarse facial features, Dense calvaria, Motor delay, Dolichocephaly, Diarrhea, Hepatomegaly, Hearing impairment, Heparan sulfate excretion in urine, Hyperactivity, Hernia, Hirsutism, Growth abnormality, Thickened ribs, Seizure, Ovoid thoracolumbar vertebrae, Autosomal recessive inheritance, Rod-cone dystrophy, Asymmetric septal hypertrophy, Intellectual disability, Loss of speech, Cellular metachromasia, Motor deterioration, Joint stiffness, Kyphoscoliosis, Variable expressivity, Sleep disturbance, Recurrent upper respiratory tract infections, Synophrys, Splenomegaly
Wie wird jemand getestet? Mucopolysaccharidosis, Type IIIC?
Die ersten Tests für Mucopolysaccharidosis, Type IIIC kann mit einem Gesichtsanalyse-Screening beginnen, durch die FDNA Telehealth Telegenetik-Plattform, die die Schlüsselmarker der syndrom und skizzieren Sie die Notwendigkeit weiterer Tests. Es folgt ein Beratungsgespräch mit einem genetischen Berater und dann einem Genetiker.
Basierend auf dieser klinischen Konsultation mit einem Genetiker werden die verschiedenen Optionen für Gentests geteilt und die Zustimmung für weitere Tests eingeholt.
Medizinische Informationen zu Mucopolysaccharidosis, Type IIIC
Mucopolysaccharidosis type III is a group of lysosomal storage diseases categorized by disrupted heparan sulfate degradation. The main clinical features are central nervous system degeneration, intellectual disability, behavioral disturbance, and mildly coarse facial features. Mucopolysaccharidosis type IIIA, which is caused by mutations in the SGSH gene, typically appears earlier in life and progresses more rapidly. This can be the most difficult form of mucopolysaccharidosis to diagnose because of the relatively mild dysmorphic features and the absence of mucopolysaccharides in the urine by some screening tests. Intellectual deterioration may be the presenting feature (Ozand et al., 1994), although mild coarsening of the facial features, hirsutism, or minimal signs of dysostosis multiplex may be noted. Growth can be mildly retarded, although increased growth with advanced bone age can occur early on. Precocious puberty can be a feature (Concolino et al., 2008). Recurrent diarrhea might be part of the presenting symptoms. Thickening of the mitral valve can be severe. Corneal clouding and hepatosplenomegaly are usually absent. Behavior is extremely difficult to manage, as there are aggression and hyperactivity. Cleary and Wraith (1993) provide a good review of the behavioral aspects and management.
Biochemically, the defect is in the breakdown of heparan sulphate. Four separate enzyme defects have been recognized, giving types A, B, C, and D.
Scott et al., (1995) cloned the sulphamidase gene and identified mutations in Sanfilippo A patients. Blanch et al., (1997), Yogalingam and Hopwood (2001), and Lee-Chen et al., (2002) reported further mutations in Sanfilippo syndrome type A. Some patients with type A present with milder disease in adulthood (Lindor et al., 1994, Miyazaki et al., 2002, Gabrielli et al., (2005). This latter patient had an R206P mutation.
Zhao et al., (1996) cloned the gene for type B. Genotype/phenotype correlations for type B mutations were reported by Zhao et al., (1998) and Schmidtchen et al., (1998). Further mutations were reported by Beesley et al., (1998), Bunge et al., (1999), Tessitore et al., (2000), and Yogalingam and Hopwood (2001).
In a cohort of 18 Sanfilippo B families reported by Beesley et al., (2005), 94% had mutations.
Nelson et al., (2003) found the incidence in Western Australia to be approximately 1 in 58,000.
Ramaswami et al., (1996) reported a case with type IIIB who presented with a transient renal tubular dysfunction at 10 weeks of age.
Zafeiriou et al., (2001) reported brain MRI findings, which can include white matter abnormalities, cortical atrophy, and ventricular enlargement.
Fraser et al., (2002) review sleep disturbance and the treatment options.
Tylki-Syzmanska et al., (2002) report three cases and provide a good review of the literature.
Van Hove et al., (2003) reported a 53-year-old woman with no neurological abnormalities but a hypertrophic cardiomyopathy. Residual heparan sulphaminidase activity was demonstrated in leukocytes and fibroblasts.
Hrebicek et al., (2006) and Fan et al., (2006) reported TMEM76 (HGSNAT) mutations in Sanfilippo type C. This codes for a transmembrane protein.
The gene for type IIIC has also now been cloned (Mok et al., 2003; Ausseil et al., 2004) and mutations found in the gene (GNS) encoding N-acetylglucosamine-6-sulfatase.
Berger-Plantiga et al., (2004) reported two adult sisters with type IIIC, who demented and had a retinitis pigmentosa.
Beesley et al., (2003) reported a homozygous mutation in the type D gene in the son of consanguineous parents, and Beesley et al., (2007) reported two Italian families with homozygous mutations.
Further mutations were reported by Jansen et al., (2007) in type D.
Valstar et. al. (2010) reported 12 patients with biallelic mutations in the GNS gene. Clinical characteristics were similar to that reported previously of all MPS III patients and included developmental delay, speech delay, behavioural problems and coarse facies.
Hu et. al., (2016) described a pair of siblings with homozygous mutation in the HGSNAT gene and clinical characteristics of Sanfilippo type C. Both developed Klüver-Bucy syndrome manifested as hyperorality, hypersexuality, prosopagnosia (face blindness), visual-sensory agnosia (psychic blindness), and hypermetamorphosis.
Wolfenden et. al., (2017) made a systematic review of symptoms of autism spectrum disorders in patients with MPS III. Data from 16 studies were included. There was an evidence that ASD-like symptoms were present in individuals with MPS III. Speech, language and communication difficulties were consistently reported but repetitive and restricted behaviour was less common.
Lavery et. al., (2017) analyzed the cause of death of patients with MPS III. In total, 84 patients for type A, 24 of type B and 5 of type c were included. Types A and B showed statistically significant improvement in life expectancy over the years. And mean age of death was greater for type C over B, and type B over A. Primary cause of death of types A and B was pneumonia.
A male patient with mild initial symptoms and hyperckemia was reported by Kartal et. al., (2017). The diagnosis of Sanfilippo was suspected by findings of dysostosis multiplex in radiological studies and later confirmed by null activity of the enzyme sulfamidase activity in leukocytes.
Knottnerus et. al., (2017) proposed a method for predicting phenotypic severity in MPS IIIA patients measuring residual SGSH activity at 30°C. Phenotypic severity correlated with the potential to increase sulfamidase activity in fibroblasts cultured at 30°C, allowing distinction between patients with rapidly progressing and slowly progressing phenotypes.
Tardieu et. al. (2017) described the clinical course of four patients with MPS III type B who underwent intracerebral gene therapy (intraparenchymal deposits of a recombinant adeno-associated viral vector encoding human NAGLU gene plus immunosuppressive therapy). Neurocognitive progression improved in all patients compared to natural history.
Zeng et. al. (2017) reported an additional patient with biallelic NAGLU gene mutations. Clinical characteristics included speech delay, rude behaviour, protruded tongue, slightly flat fifth lumbar vertebra, and cognitive decline. No typical signs associated with MPS IIIB such as coarse facies, hepatomegaly, or skeletal findings were documented.
Velasco et. al. (2017), described five interrelated patients with homozygous missense mutations in the HGSNAT gene. An earlier presentation of some neurological symptoms (epilepsy, loss of language, loss of ambulation) was observed.
* This information is courtesy of the L M D.
If you find a mistake or would like to contribute additional information, please email us at: [email protected]
Erhalten Sie eine schnellere und genauere Genetische Diagnostik!
Mehr als 250,000 Patienten erfolgreich analysiert!
Warten Sie nicht Jahre auf eine Diagnose. Handeln Sie jetzt und sparen Sie wertvolle Zeit.
Was ist FDNA Telehealth?
FDNA Telehealth ist ein führendes Unternehmen für digitale Gesundheit, das einen schnelleren Zugang zu genauen genetischen Analysen bietet.
Mit einer von führenden Genetikern empfohlenen Krankenhaustechnologie verbindet unsere einzigartige Plattform Patienten mit Genexperten, um ihre dringendsten Fragen zu beantworten und eventuelle Bedenken hinsichtlich ihrer Symptome zu klären.
Vorteile von FDNA Telehealth
Unsere Plattform wird derzeit von über 70% der Genetiker verwendet und wurde zur Diagnose von über 250,000 Patienten weltweit eingesetzt.
FDNA Telehealth bietet innerhalb von Minuten eine Gesichtsanalyse und ein Screening, gefolgt von einem schnellen Zugang zu genetischen Beratern und Genetikern.
Unser nahtloser Prozess beginnt mit einer ersten Online-Diagnose durch einen genetischen Berater, gefolgt von Konsultationen mit Genetikern und Gentests.
Genauigkeit & Präzision
Erweiterte Funktionen und Technologien für künstliche Intelligenz (KI) mit einer Genauigkeitsrate von 90% für eine genauere genetische analyse.
Schnellerer Zugang zu genetischen Beratern, Genetikern, Gentests und einer Diagnose. Falls erforderlich, innerhalb von 24 Stunden. Sparen Sie Zeit und Geld.
Privatsphäre & Sicherheit
Wir garantieren den größtmöglichen Schutz aller Bilder und Patienteninformationen. Ihre Daten sind immer sicher und verschlüsselt.